| Identification | Back Directory | [Name]
Pyridine, 3-methoxy-2,6-dimethyl-4-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methoxy]- | [CAS]
139958-16-0 | [Synonyms]
ME3221
ME-3221
ME 3221
Pyridine, 3-methoxy-2,6-dimethyl-4-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methoxy]- | [Molecular Formula]
C22H21N5O2 | [MOL File]
139958-16-0.mol | [Molecular Weight]
387.43 |
| Hazard Information | Back Directory | [Description]
ME-3221 is an angiotensin type 1 receptor antagonist potentially for the treatment of hypertension. ME3221 prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats. n rats and marmosets, ME3221 antagonized angiotensin II-induced pressor responses, but did not affect bradykinin-induced depressor responses. ME3221 lowered the blood pressure in renal hypertensive rats and spontaneously hypertensive rats (SHR), and its ED25 value was 3 times that of losartan. | [Uses]
ME3221 is an angiotensin AT1 receptor antagonist that effectively antagonizes the pressor response to angiotensin II in rats and marmosets without affecting the hypotensive response to bradykinin. It demonstrates potent antihypertensive effects in renal hypertensive rats and spontaneously hypertensive rats (SHR), with efficacy comparable to or better than losartan in vivo. ME3221's repeated administration in SHR results in sustained and stable hypotensive effects without affecting heart rate, indicating its potential for treating both renal and essential hypertension similarly to losartan[1]. | [References]
[1] Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist |
|
|